Skip to content

Search

Showing results for "8"

An evening for the future of autism

Join Dr Andrew Whitehouse, head of Developmental Disorders research at The Kids, as he shares with you his vision for autism research.

Perth children and seniors needed for bird flu vaccine study

Perth researchers have begun a trial to test the effectiveness in children and seniors of a new vaccine to protect against the potentially deadly bird flu.

Survey results

Download the Young Minds Matter report and overview, watch video snapshots and access survey results and tables.

Pneumococcal Vaccine Study

Researchers at The Kids Research Institute Australia are studying a new pneumococcal vaccine designed to provide a broader protection for 21 serotypes of the bacteria S. pneumoniae – 8 more serotypes than the current vaccine given to new babies.

Congratulations Kate and Aveni

Fantastic news for two of our talented researchers whose papers were featured in the Advanced Technologies & Treatments for Diabetes (ATTD) 2024 Yearbook.

Joint Attention, Symbolic Play, Engagement and Regulation

At CliniKids, the JASPER approach is for preschool and school-aged children who have differences in play and social communication skills.

Understanding Engagement in Digital Mental Health and Well-being Programs for Women in the Perinatal Period: Systematic Review Without Meta-analysis

Pregnancy and the postnatal period can be a time of increased psychological distress, which can be detrimental to both the mother and the developing child. Digital interventions are cost-effective and accessible tools to support positive mental health in women during the perinatal period.

Azithromycin mitigates human rhinovirus impact on barrier integrity and function in non-diseased airway epithelium

Azithromycin improves symptomology in various chronic airway diseases exacerbated by viral infections. However, the mechanisms underlying the apparent antiviral effects of azithromycin remain unclear.

EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses

High-grade gliomas including glioblastoma (GBM) and diffuse midline gliomas (DMG) represent the most lethal and aggressive brain cancers where current treatment modalities offer limited efficacy. Chimeric antigen receptor (CAR) T cell therapies have emerged as a promising strategy, boasting tumor-specific targeting and the unique ability to penetrate the blood-brain barrier.